SpringWorks Therapeutics' Breakthrough Cancer Treatment Receives FDA Approval
TL;DR Summary
The FDA has granted approval to Springworks Therapeutics for their drug Ogsiveo, making it the first treatment available for desmoid tumors, a localized cancer that affects soft tissue and muscle. Desmoid tumors, although non-metastatic, can cause significant pain and disability. Currently, there are no approved therapies for this condition, with doctors resorting to off-label treatments such as chemotherapy, targeted therapies, radiation, and surgery.
- Springworks wins FDA approval for drug to treat desmoid tumors STAT
- US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment Reuters
- Biotech Catapults 24% On A 'Watershed Moment' In Cancer Treatment Investor's Business Daily
- FDA approves Pfizer spinout SpringWorks' cancer drug Ogsiveo FiercePharma
- FDA Approves Nirogacestat for Desmoid Tumors OncLive
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
17
Time Saved
0 min
vs 1 min read
Condensed
48%
122 → 63 words
Want the full story? Read the original article
Read on STAT